EOS Med Chem, Medicinal Chemical is Big: Stock 50g, Pibrentasvir (ABT-530), Cas:1353900-92-1

Pibrentasvir (ABT-530), Cas:1353900-92-1, we are sole GMP supplier, could provide you full document, like COA, HPLC, HNMR, MSDS, ROS.

Pibrentasvir (ABT-530) Intermediate: 1332357-14-8, 5, 5'-[(2R, 5R)-1-[3,5-difluoro-4-(4-(4-fluorophenyl)- 1-piperidinyl)phenyl]-2,5-pyrrolidinediyl]bis[6-fluoro-2-(2S)-2-pyrrolidinyl 1H-benzimidzole], stock more than 11kg, HPLC, HNMR, COA, MSDS, ROS is ok.

Pibrentasvir (ABT-530) Intermediate: 1890114-11-0, (2S,2'S)-[[(2R, 5R)-1-[3,5-difluoro-4-(4-(4- fluorophenyl)-1-piperidinyl)phenyl]-2,5-pyrrolidinediyl]bis[6-fluoro-2-(2S)-2-pyrrolidinyl 1H-benzimidzol e-2,5-diyl)]bis(1-pyrrolidinecarboxylic acid, 1,1'-bis(1,1'-dimethylethyl)ester, stock more than 11kg, HPLC, HNMR, COA, MSDS, ROS is ok.

Pibrentasvir (ABT-530) Intermediate: 1292836-20-4, (1S,4S)-1,4-bis(4-chloro-2-fluoro-5-nitrophenyl)butane-1,4-diol, stock more than 11kg, HPLC, HNMR, COA, MSDS, ROS is ok.

Pibrentasvir (ABT-530) Intermediate: 1332356-31-6,3,5-difluoro-4-(4-(4-fluorophenyl)piperidin-1-yl)aniline, stock more than 11kg, HPLC, HNMR, COA, MSDS, ROS is ok.

Description: Pibrentasvir is a protease inhibitor potentially for the treatment of HCV infection.

Name: Pibrentasvir

CAS#: 1353900-92-1

Chemical Formula: C57H65F5N10O8

Exact Mass: 1112.4907

Molecular Weight: 1113.2

Elemental Analysis: C, 61.50; H, 5.89; F, 8.53; N, 12.58; O, 11.50

Synonym: ABT-530; ABT530; ABT 530, Pibrentasvir.

IUPAC/Chemical Name: dimethyl ((2S,2'S,3R,3'R)-((2S,2'S)-(((2R,5R)-1-(3,5-difluoro-4-(4-(4-fluorophenyl)piperidin-1-yl)phenyl)pyrrolidine-2,5-diyl)bis(6-fluoro-1H-benzo[d]imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methoxy-1-oxobutane-1,2-diyl))dicarbamate

InChi Key: VJYSBPDEJWLKKJ-NLIMODCCSA-N

InChi Code: InChI=1S/C57H65F5N10O8/c1-29(77-3)49(67-56(75)79-5)54(73)70-19-7-9-47(70)52-63-41-25-35(37(59)27-43(41)65-52)45-15-16-46(72(45)34-23-39(61)51(40(62)24-34)69-21-17-32(18-22-69)31-11-13-33(58)14-12-31)36-26-42-44(28-38(36)60)66-53(64-42)48-10-8-20-71(48)55(74)50(30(2)78-4)68-57(76)80-6/h11-14,23-30,32,45-50H,7-10,15-22H2,1-6H3,(H,63,65)(H,64,66)(H,67,75)(H,68,76)/t29-,30-,45-,46-,47+,48+,49+,50+/m1/s1

SMILES Code: FC1=CC=C(C2CCN(C3=C(F)C=C(N4[C@@H](C5=C(F)C=C6C(N=C([C@H]7N(C([C@@H](NC(OC)=O)[C@H](OC)C)=O)CCC7)N6)=C5)CC[C@@H]4C8=C(F)C=C9C(N=C([C@H]%10N(C([C@@H](NC(OC)=O)[C@H](OC)C)=O)CCC%10)N9)=C8)C=C3F)CC2)C=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code: 293490

REFERENCES

1: Ng TI, Krishnan P, Pilot-Matias T, Kati W, Schnell G, Beyer J, Reisch T, Lu L, Dekhtyar T, Irvin M, Tripathi R, Maring C, Randolph JT, Wagner R, Collins C. In Vitro Antiviral Activity and Resistance Profile of the Next Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. Antimicrob Agents Chemother. 2017 Feb 13. pii: AAC.02558-16. doi: 10.1128/AAC.02558-16. [Epub ahead of print] PubMed PMID: 28193664.

2: Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, Gordon SC, Flamm SL, Fried MW, Bernstein DE, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and Pibrentasvir for 12 Weeks for HCV Genotype 1 Infection and Prior Direct-acting Antiviral Treatment. Hepatology. 2017 Jan 27. doi: 10.1002/hep.29081. [Epub ahead of print] PubMed PMID: 28128852.

3: Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezari J, Wyles DL, Hassanein T, Aguilar H, Maliakkal B, Liu R, Lin CW, Ng TI, Kort J, Mensa FJ. High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. Gastroenterology. 2016 Oct;151(4):651-659.e1. doi: 10.1053/j.gastro.2016.07.020. PubMed PMID: 27456384.